First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease
Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
PR Newswire
THOUSAND OAKS, Calif., Nov. 16, 2018